ITMI972690A1 - Uso di complessi di estratti vitis vinifera con fosfolipidi come agenti anti-arteriosclerotici - Google Patents
Uso di complessi di estratti vitis vinifera con fosfolipidi come agenti anti-arteriosclerotici Download PDFInfo
- Publication number
- ITMI972690A1 ITMI972690A1 IT97MI002690A ITMI972690A ITMI972690A1 IT MI972690 A1 ITMI972690 A1 IT MI972690A1 IT 97MI002690 A IT97MI002690 A IT 97MI002690A IT MI972690 A ITMI972690 A IT MI972690A IT MI972690 A1 ITMI972690 A1 IT MI972690A1
- Authority
- IT
- Italy
- Prior art keywords
- vitis vinifera
- phospholipids
- treatment
- complexes
- medicament
- Prior art date
Links
- 235000014787 Vitis vinifera Nutrition 0.000 title claims abstract description 11
- 240000006365 Vitis vinifera Species 0.000 title claims abstract description 11
- 235000002532 grape seed extract Nutrition 0.000 title claims abstract description 11
- 150000003904 phospholipids Chemical class 0.000 title claims abstract description 11
- 239000000284 extract Substances 0.000 title claims abstract description 8
- 239000003814 drug Substances 0.000 claims description 6
- 201000001320 Atherosclerosis Diseases 0.000 claims description 5
- 206010008118 cerebral infarction Diseases 0.000 claims description 3
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 3
- 229920002770 condensed tannin Polymers 0.000 claims description 3
- 238000009109 curative therapy Methods 0.000 claims description 2
- 239000007903 gelatin capsule Substances 0.000 claims description 2
- 230000003449 preventive effect Effects 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000003143 atherosclerotic effect Effects 0.000 abstract description 4
- 230000001575 pathological effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000003902 lesion Effects 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000000260 hypercholesteremic effect Effects 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 2
- 210000002376 aorta thoracic Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 1
- 108010069201 VLDL Cholesterol Proteins 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- GGCLNOIGPMGLDB-GYKMGIIDSA-N cholest-5-en-3-one Chemical compound C1C=C2CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 GGCLNOIGPMGLDB-GYKMGIIDSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000009552 doppler ultrasonography Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920002414 procyanidin Polymers 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E50/00—Technologies for the production of fuel of non-fossil origin
- Y02E50/30—Fuel from waste, e.g. synthetic alcohol or diesel
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Solid Fuels And Fuel-Associated Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
"USO DI COMPLESSI DI ESTRATTI VITIS VINIFERA CON FOSFOLIPIDI COME AGENTI ANTI-ATEROSCLEROTICI"
La presente invenzione riguarda l’uso di complessi di fosfolipidi con proantocianidine oligomeriche da 2 a 7 unità catechiche estratte da Vitis vinifera per la preparazione di medicamenti per il trattamento sia preventivo che curativo dell'aterosclerosi, dell'infarto cardiaco e cerebrale.
Gli estratti di Vitis vinifera sono già noti e trovano applicazione nella terapia di disturbi cardiovascolari legati all'insufficienza venosa, nel trattamento di alterati stati di permeabilità e resistenza capillare e nella cicatrizzazione. Questi estratti, che possono essere ottenuti dai semi della pianta come descritto in GB-A-1541469 o FR-A-2092743, sono costituiti da una miscela di sostanze polifenoliche quali 1'epicatechina e suoi prodotti di polimerizzazione in parte esterificati all'idrossile in C-3 del monomero con acido gallico. I conplessi con fosfolipidi degli estratti di Vitis vinifera sono descritti in US-4,963,527 e sono attualmente disponibili in commercio con il marchio Leucoselect.
Si è ora sorprendentemente trovato che i complessi preparati secondo US-4,963,527 esplicano, quando somministrati per via sistemica, preferibilmente per via orale, una marcata attività antiaterosclerotica sia nell'animale sia nell'uomo.
Si è trovato in particolare che i conplessi di fosfolipidi con proantocianidine oligomeriche da 2 a 7 unità catechiche estratte da Vitis vinifera evitano o riducono la formazione di placche aterosclerotiche in modo proporzionale alla dose somministrata. L'attività è stata evidenziata in conigli alimentati a dieta ipercolesterolemica, tale da provocare lesioni aterosclerotiche simili a quelle umane a livello vascolare, particolarmente a livello di arco aortico, aorta ventrale, cariotidi e vasi cerebrali. In tale modello i sopramenzionati complessi con fosfolipidi cambiano l'assetto macro e microscopico vascolare, riducendo, rispetto agli animali non trattati, sia il numero di placche ateromatose sia la loro gravità, con un · sorprendente beneficio vasculo-tissatale. In un altro modello di aterosclerosi con intendimento di protezione cerebrale, nel quale il lume vasale della carotide interna del coniglio viene chirurgicamente ridotto somministrando simultaneamente una dieta ipercolesterolemica e ricca in grassi saturi, sono stati evidenziati ima diminuzione dell'ostruzione carotidea, un appiattimento delle pareti vascolari ed una migliorata sopravvivenza degli animali.Anche in pazienti affetti da aterosclerosi, si sono notati, a sei mesi dal trattamento, una riduzione dell'ostruzione carotidea dovuta alle placche ateromatose e un migliorato flusso carotideo valutati mediante ultrasonografia doppler. I complessi con fosfolipidi delle procianidine estratte da Vitis vinifera possono essere usati in convenienti forme di somministrazione per la via orale quali compresse, capsule di gelatina molle o dura, a dosaggi compresi fra 50 e 500 mg per due-tre volte al giorno, a seconda della gravità della patologia da trattare. La preparazione delle formulazioni farmaceutiche può essere effettuata ricorrendo a tecniche ed eccipienti convenzionali.
I seguenti esempi illustrano l'invenzione in maggior dettaglio.
Dopo 8 settimane di trattamento, nel corso delle quali sono stati misurati i livelli di colesterolo, LDL/VLDL, HDL e trigliceridi, gli animali furono sacrificati.
Sono stati valutati il numero, la dimensione e la distribuzione delle lesioni aterosclerotiche a carico dell'aorta toracica e addominale.
I reperti autoptici sono stati fissati e colorati con Sudan IV per visualizzare le lesioni e per determinare il colesterolo vasale e il contenuto di colesterolo ossidato mediante gascromatografia.
I risultati,riportati nella successiva tabella, dimostrano che il trattamento con complessi di fosfolipidi di estratti di Vitis vinifera è in grado di ridurre in modo statisticamente significativo l'entità delle lesioni aterosclerotiche indotte dalla dieta ipercolesterolemica .
Claims (5)
- RIVENDICAZIONI 1. Uso di conplessi di fosfolipidi con proantocianidine oligomeriche·da 2 a 7 unità catechiche estratte da Vitis vinifera per la preparazione di medicamenti per la preparazione di medicamenti per il trattamento preventivo e curativo dell'aterosclerosi, dell'infarto cardiaco e cerebrale.
- 2. Uso secondo la rivendicazione 1 in cui il medicamento ha un dosaggio unitario conpreso tra 50 e 500 mg di principio attivo.
- 3. Uso secondo la rivendicazione 1 o 2 in cui il medicamento è somministrabile per via orale.
- 4... Uso secondo la rivendicazione 3 in cui il medicamento è sotto forma di capsule di gelatina molle o dura o di conpresse.
- 5. Metodo per il trattamento di aterosclerosi, infarto cardiaco e cerebrale, che conprende la somministrazione ad un paziente di una quantità efficace di un conplesso di estratto di Vitis vinifera con fosfolipidi.
Priority Applications (23)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT97MI002690A IT1296920B1 (it) | 1997-12-04 | 1997-12-04 | Uso di complessi di estratti vitis vinifera con fosfolipidi come agenti anti-aterosclerotici |
| KR1020007005420A KR100567867B1 (ko) | 1997-12-04 | 1998-11-30 | 포도 추출물의 인지질 착체화합물의 아테롬성동맥경화치료제로서의 용도 |
| JP2000524000A JP4456267B2 (ja) | 1997-12-04 | 1998-11-30 | 抗アテローム性動脈硬化剤としてのヴィティス・ヴィニフェラ（ｖｉｔｉｓｖｉｎｉｆｅｒａ）抽出物のリン脂質複合体の使用 |
| SI9830609T SI1035859T1 (en) | 1997-12-04 | 1998-11-30 | The use of phospholipid complexes of extracts of vitis vinifera as anti-atherosclerotic agents |
| CZ20002038A CZ299555B6 (cs) | 1997-12-04 | 1998-11-30 | Farmaceutický prostredek |
| CA002312795A CA2312795C (en) | 1997-12-04 | 1998-11-30 | The use of phospholipid complexes of extracts of vitis vinifera as anti-atherosclerotic agents |
| RU2000114174/14A RU2207866C2 (ru) | 1997-12-04 | 1998-11-30 | ПРИМЕНЕНИЕ ФОСФОЛИПИДНЫХ КОМПЛЕКСОВ ЭКСТРАКТОВ ИЗ vitis vinifera В КАЧЕСТВЕ ПРОТИВОАТЕРОСКЛЕРОТИЧЕСКИХ АГЕНТОВ |
| PT98959890T PT1035859E (pt) | 1997-12-04 | 1998-11-30 | Utilizacao de complexos de fosfolipidos de extractos de vitis vinifera como agentes anti-ateroescleroticos |
| EP98959890A EP1035859B1 (en) | 1997-12-04 | 1998-11-30 | The use of phospholipid complexes of extracts of vitis vinifera as anti-atherosclerotic agents |
| ES98959890T ES2214755T3 (es) | 1997-12-04 | 1998-11-30 | Uso de complejos de fosfolipidos de extractos de vitis vinifera como agentes antiateroescleroticos. |
| AT98959890T ATE258802T1 (de) | 1997-12-04 | 1998-11-30 | Verwendung von vitis vinifera extrakten phospholipid komplexen als antiatherosclerotische mitteln |
| CN98811768A CN1126564C (zh) | 1997-12-04 | 1998-11-30 | 葡萄提取物的膦脂复合物作为抗动脉粥样硬化剂的应用 |
| AU15627/99A AU743031B2 (en) | 1997-12-04 | 1998-11-30 | The use of phospholipid complexes of extracts of vitis vinifera as anti-atherosclerotic agents |
| HU0100522A HU228109B1 (en) | 1997-12-04 | 1998-11-30 | The use of phospholipid complexes of vitis vinifera extracts for producing medicaments as anti-atherosclerotic agents |
| SK827-2000A SK284865B6 (sk) | 1997-12-04 | 1998-11-30 | Použitie fosfolipidových komplexov oligomérnych proantokyanidov extrahovaných z Vitis vinifera na prevenciu a liečenie aterosklerotických patologických ťažkostí |
| DK98959890T DK1035859T3 (da) | 1997-12-04 | 1998-11-30 | Anvendelse af phospholipidkomplekser fra ekstrakter af Vitis vinifera som anti-atherosklerotiske midler |
| PCT/EP1998/007662 WO1999029331A1 (en) | 1997-12-04 | 1998-11-30 | The use of phospholipid complexes of extracts of vitis vinifera as anti-atherosclerotic agents |
| DE69821524T DE69821524T2 (de) | 1997-12-04 | 1998-11-30 | Verwendung von vitis vinifera extrakten phospholipid komplexen als antiatherosclerotische mitteln |
| PL340884A PL191023B1 (pl) | 1997-12-04 | 1998-11-30 | Zastosowanie kompleksów fosfolipidowych z ekstraktów z Vitis vinifera jako środki przeciwmiażdżycowe |
| BRPI9805813-4A BR9805813B1 (pt) | 1997-12-04 | 1998-12-29 | composição combustìvel sólida e processo para preparar a mesma. |
| US09/580,906 US6297218B1 (en) | 1997-12-04 | 2000-05-31 | Phospholipid complexes prepared from extracts of Vitis vinifera as anti-atherosclerotic agents |
| NO20002827A NO324796B1 (no) | 1997-12-04 | 2000-06-02 | Anvendelse av fosfolipidkomplekser ekstrahert fra Vitis vinifera ved fremstilling av antiaterosklerotiske midler. |
| HK01103945A HK1033267A1 (en) | 1997-12-04 | 2001-06-08 | The use of phospholipid complexes of extracts of vitis vinifera as anti-atherosclerotic agents |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT97MI002690A IT1296920B1 (it) | 1997-12-04 | 1997-12-04 | Uso di complessi di estratti vitis vinifera con fosfolipidi come agenti anti-aterosclerotici |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ITMI972690A1 true ITMI972690A1 (it) | 1999-06-04 |
| IT1296920B1 IT1296920B1 (it) | 1999-08-03 |
Family
ID=11378312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT97MI002690A IT1296920B1 (it) | 1997-12-04 | 1997-12-04 | Uso di complessi di estratti vitis vinifera con fosfolipidi come agenti anti-aterosclerotici |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US6297218B1 (it) |
| EP (1) | EP1035859B1 (it) |
| JP (1) | JP4456267B2 (it) |
| KR (1) | KR100567867B1 (it) |
| CN (1) | CN1126564C (it) |
| AT (1) | ATE258802T1 (it) |
| AU (1) | AU743031B2 (it) |
| BR (1) | BR9805813B1 (it) |
| CA (1) | CA2312795C (it) |
| CZ (1) | CZ299555B6 (it) |
| DE (1) | DE69821524T2 (it) |
| DK (1) | DK1035859T3 (it) |
| ES (1) | ES2214755T3 (it) |
| HK (1) | HK1033267A1 (it) |
| HU (1) | HU228109B1 (it) |
| IT (1) | IT1296920B1 (it) |
| NO (1) | NO324796B1 (it) |
| PL (1) | PL191023B1 (it) |
| PT (1) | PT1035859E (it) |
| RU (1) | RU2207866C2 (it) |
| SI (1) | SI1035859T1 (it) |
| SK (1) | SK284865B6 (it) |
| WO (1) | WO1999029331A1 (it) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1304183B1 (it) * | 1998-12-18 | 2001-03-08 | Indena Spa | Complessi di proantocianidina a2 con fosfolipidi come agentiantiaterosclerotici. |
| JP2001122791A (ja) | 1999-10-20 | 2001-05-08 | Boehringer Ingelheim Internatl Gmbh | 下肢の慢性静脈不全の軽減および予防のための赤色ブドウ樹葉の水性抽出物よりなる食事補強剤 |
| JP4574788B2 (ja) * | 2000-03-24 | 2010-11-04 | 協和発酵バイオ株式会社 | プロアントシアニジン含有組成物 |
| IT1320080B1 (it) * | 2000-10-25 | 2003-11-18 | Giuliani Spa | Composizione per uso farmaceutico o dietetico. |
| FR2836337B1 (fr) * | 2002-02-28 | 2004-11-19 | Bio Serae Laboratoires | Utilisation des polymeres procyanidoliques a titre d'agents inhibuteurs des alpha-amylases et application dans des compositions a visees dietetiques |
| KR20050095834A (ko) * | 2002-12-31 | 2005-10-04 | 베링거 인겔하임 인터내셔날 게엠베하 | 레드바인 잎 추출물을 포함하는 필름 코팅 정제 |
| US20040151769A1 (en) * | 2002-12-31 | 2004-08-05 | Boehringer Ingelheim International Gmbh | Film coated tablet containing an extract of red vine leaves |
| ITMI20031313A1 (it) * | 2003-06-27 | 2004-12-28 | Indena Spa | Associazioni di agenti vasoprotettori e formulazioni che li contengono. |
| EP1550450A1 (en) * | 2003-12-29 | 2005-07-06 | Boehringer Ingelheim International GmbH | Composition comprising an aqueous extract of red vine leaves and a blood circulating-improving agent for the treatment of chronic venous insufficiencies |
| EP1718168A1 (en) | 2004-02-19 | 2006-11-08 | Boehringer Ingelheim International Gmbh | Composition for the treatment of chronic venous insufficiencies comprising an extract of red vine leaves and an anti-inflammatory agent |
| US20060088617A1 (en) * | 2004-10-23 | 2006-04-27 | Mccurry James M | Chocolate composition and method for benefiting the cardiovascular system |
| AT501682A1 (de) | 2005-01-14 | 2006-10-15 | Hermine Dr Engl | Verfahren zur herstellung einer wirkstoffmischung |
| EP1837030A1 (en) | 2006-03-09 | 2007-09-26 | INDENA S.p.A. | Phospholipid complexes of curcumin having improved bioavailability |
| EP2829277A1 (en) | 2013-07-26 | 2015-01-28 | Natac Biotech, S.L. | Use of a-type proanthocyanidins in treating a mineralocorticoid receptor related disease |
| WO2019087084A1 (en) | 2017-11-02 | 2019-05-09 | Eman Biodiscoveries Sd. Bhd. | Extract of orthosiphon stamineus, formulations, and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2092743A1 (en) * | 1970-06-15 | 1972-01-28 | Aquitaine Invest Pharma | Complete extraction of total flavanol gomers from plats -peripheral - venous activity |
| GB1541469A (en) * | 1976-12-01 | 1979-02-28 | Inverni Della Beffa Spa | Method of obtaining flavonolic oligomers |
| IT1201151B (it) * | 1987-01-14 | 1989-01-27 | Indena Spa | Complessi fosfolipidici con estratti da vitis vinifera,procedimento per la loro preparazione e composizioni che li cntengono |
| US5484594A (en) * | 1988-06-28 | 1996-01-16 | Tecnofarmaci S.P.A. | Process for preparing grapeseed extracts enriched in procyanidol oligomers |
| FI955691A (fi) | 1994-11-28 | 1996-05-29 | Suntory Ltd | Lipoproteiini(a):ta alentava aine, kolesterolia alentava aine ja näitä aineita sisältävät lääkkeet |
-
1997
- 1997-12-04 IT IT97MI002690A patent/IT1296920B1/it active IP Right Grant
-
1998
- 1998-11-30 CZ CZ20002038A patent/CZ299555B6/cs not_active IP Right Cessation
- 1998-11-30 CN CN98811768A patent/CN1126564C/zh not_active Expired - Fee Related
- 1998-11-30 DK DK98959890T patent/DK1035859T3/da active
- 1998-11-30 JP JP2000524000A patent/JP4456267B2/ja not_active Expired - Fee Related
- 1998-11-30 KR KR1020007005420A patent/KR100567867B1/ko not_active IP Right Cessation
- 1998-11-30 AT AT98959890T patent/ATE258802T1/de active
- 1998-11-30 SK SK827-2000A patent/SK284865B6/sk not_active IP Right Cessation
- 1998-11-30 DE DE69821524T patent/DE69821524T2/de not_active Expired - Lifetime
- 1998-11-30 AU AU15627/99A patent/AU743031B2/en not_active Ceased
- 1998-11-30 EP EP98959890A patent/EP1035859B1/en not_active Expired - Lifetime
- 1998-11-30 WO PCT/EP1998/007662 patent/WO1999029331A1/en active IP Right Grant
- 1998-11-30 PL PL340884A patent/PL191023B1/pl not_active IP Right Cessation
- 1998-11-30 RU RU2000114174/14A patent/RU2207866C2/ru not_active IP Right Cessation
- 1998-11-30 CA CA002312795A patent/CA2312795C/en not_active Expired - Fee Related
- 1998-11-30 ES ES98959890T patent/ES2214755T3/es not_active Expired - Lifetime
- 1998-11-30 SI SI9830609T patent/SI1035859T1/xx unknown
- 1998-11-30 HU HU0100522A patent/HU228109B1/hu not_active IP Right Cessation
- 1998-11-30 PT PT98959890T patent/PT1035859E/pt unknown
- 1998-12-29 BR BRPI9805813-4A patent/BR9805813B1/pt not_active IP Right Cessation
-
2000
- 2000-05-31 US US09/580,906 patent/US6297218B1/en not_active Expired - Lifetime
- 2000-06-02 NO NO20002827A patent/NO324796B1/no not_active IP Right Cessation
-
2001
- 2001-06-08 HK HK01103945A patent/HK1033267A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ITMI972690A1 (it) | Uso di complessi di estratti vitis vinifera con fosfolipidi come agenti anti-arteriosclerotici | |
| US20070098808A1 (en) | Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases arthritis, skin cancer diabetes, premenstrual syndrome and transdermal transport | |
| SK10802001A3 (sk) | Esenciálne mastné kyseliny na prevenciu kardiovaskulárnych príhod | |
| ES2340510T3 (es) | Uso de alquil-furanos para la preparacion de un medicamento destinado al tratamiento de la obesidad y para el tratamiento cosmetico del exceeso de peso. | |
| CN101878028A (zh) | 作为肾保护剂的中链长度脂肪酸和甘油酯 | |
| AU2001260833B2 (en) | Treating eczema and/or psoriasis | |
| AU2001260833A1 (en) | Treating eczema and/or psoriasis | |
| ITMI982732A1 (it) | Complessi di proantocianidina a2 con fosfilipidi come agentiantiaterosclerotici. | |
| US8586064B2 (en) | Treating eczema and/or psoriasis | |
| JP2020528462A (ja) | 片頭痛の予防及び治療に使用するための栄養補助食品 | |
| NZ522434A (en) | Treating eczema and/or psoriasis | |
| JP2000327571A (ja) | 抗かゆみ組成物 | |
| RO128803A0 (ro) | Compoziţie pentru tratamentul sau prevenirea dislipidemiilor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 0001 | Granted |